Calyxt, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Supplemental Information (Tables)

Supplemental Information (Tables)

9 Months Ended

Sep. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Certain Balance Sheet Amounts

Certain balance sheet amounts are as follows:


	As of September 30,				As of December 31,
In Thousands	2021				2020
Accounts Receivable:
Accounts receivable	$	199			$	4,317
Receivables from growers		7				570
Allowance for doubtful accounts		—				—
Total	$	206			$	4,887

Schedule of Certain Statements of Operations Amounts

Certain statements of operations amounts are as follows:


	Three Months Ended September 30,								Nine Months Ended September 30,
In Thousands	2021				2020				2021				2020
Stock compensation expense:
Research and development	$	252			$	(84	)		$	1,061			$	723
Selling, general, and administrative		984				654				(196	)			2,915
Total	$	1,236			$	570			$	865			$	3,638


	Three Months Ended September 30,								Nine Months Ended September 30,
In Thousands	2021				2020				2021				2020
Interest, net:
Interest expense	$	(356	)		$	(369	)		$	(1,075	)		$	(1,112	)
Interest income		—				45				16				544
Total	$	(356	)		$	(324	)		$	(1,059	)		$	(568	)

Schedule of Certain Statements of Balance sheet and cash flows amounts

Certain balance sheet and statements of cash flows amounts are as follows:


	As of September 30,				As of December 31,				As of September 30,
In Thousands	2021				2020				2020
Cash, cash equivalents, restricted cash, and short-term investments:
Cash and cash equivalents	$	13,922			$	17,299			$	7,170
Restricted cash		393				393				393
Non-current restricted cash		598				597				1,041
Total cash, cash equivalents, and restricted cash		14,913				18,289				8,604
Short-term investments		—				11,698				20,802
Total	$	14,913			$	29,987			$	29,406